Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifetroban in high-risk malignant solid tumors
NCT03694249Phase 2Active, not recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2018
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifetroban in malignant solid tumor, sponsored by Vanderbilt-Ingram Cancer Center. Started Dec 2018; status: active, not recruiting.
02
Drugs
ifetroban
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT03694249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694249.